COMPASS Pathways (CMPS) is back in focus after recent share price swings, with the mental health biotech drawing attention as ...

Compass Pathways Plc marked the opening of its U.S. office in Jersey City on Oct. 5 with a ribbon-cutting ceremony.

COMPASS Pathways has been back in the spotlight, with fresh clinical data on its COMP360 psilocybin therapy and a sharply higher share price putting a simple question on the table. After such a move, ...

Compass Pathways has already reported two positive phase 3 trials for treatment-resistant depression (TRD). The company's COMP360 synthetic psilocybin treatment could now be on a faster track for ...

COMPASS Pathways stock was last at USD 11.90 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, down 0.42 percent from USD 11.95.

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today celebrated the opening of its new U.S. office in ...

The precipitous fall occurred on Monday, 06/23/2025 when the stock dropped from its close at $4.63 on the previous Friday to open Monday at $3.08. It hit an interday low of $2.25, closing the hectic ...

COMPASS Pathways focuses on developing COMP360 psilocybin for treatment-resistant depression, facing significant challenges due to its Schedule I status. Key risks include market acceptance, ...

LONDON, NEW YORK - Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced that Compass granted ...

Participants received a single dose of either 25 mg of COMP360 or placebo On track for disclosure of top-line 6-week primary endpoint results in late June LONDON & NEW YORK--(BUSINESS WIRE)--Compass ...

COMPASS Pathways stock (ISIN US20451W1018) stood at USD 13.75 in after-hours trading on Nasdaq on September 23, 2026, down ...